Matthew T. Campbell

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-1915-4491

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 28 papers. Top paper: “Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies”.

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

Cancer(2020)10.1002/cncr.33328

N/A

3.1DataRank · unranked

113 citations

Matthew T. Campbell, Wanling Xie, Subrina Farah, Mehmet Asım Bilen, Andrew Schmidt +11 more

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

The Oncologist(2021)10.1002/onco.13682

N/A

1.4DataRank · unranked

47 citations

Henry Hiep Vo, Vivek Subbiah, Filip Jankú, Sarina A. Piha‐Paul, Bülent Yılmaz +7 more

Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00133-5

N/A

0.850DataRank · unranked

29 citations

Mouhammed Amir Habra, Matthew T. Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James P. Long +6 more

Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00095-0

N/A

0.807DataRank · unranked

27 citations

Vania Balderrama-Brondani, Camilo Jiménez, Gina Tamsen, Leonardo P. Marcal, Jeena Varghese +7 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0.670DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

Science Translational Medicine(2022)10.1126/scitranslmed.abm6420

N/A

0.633DataRank · unranked

67 citations

Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric Jonasch +21 more

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001009

N/A

0.606DataRank · unranked

56 citations

Kevin C. Miller, Lina Altameemi, M. Shaaban Ali, Sameh Nassar, Naveen Garg +10 more

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-38342-7

N/A

0.587DataRank · unranked

49 citations

Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita +17 more

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies

The Oncologist(2021)10.1002/onco.13770

N/A

0.546DataRank · unranked

37 citations

Tharakeswara Bathala, Andrew W. Hahn, Lianchun Xiao, Munevver Duran, Jeremy A. Ross +6 more

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma

The Journal of Urology(2024)10.1097/ju.0000000000003928

N/A

0.411DataRank · unranked

8 citations

Mehrad Adibi, Amishi Y. Shah, Omar Alhalabi, Paul G. Corn, Charles C. Guo +8 more

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Nature Communications(2025)10.1038/s41467-025-57009-z

N/A

0.406DataRank · unranked

14 citations

Jianjun Gao, Sreyashi Basu, Daniel D. Shapiro, José A. Karam, Rebecca S. Tidwell +22 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0.373DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0.165DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis

The Oncologist(2024)10.1093/oncolo/oyae099

N/A

0.165DataRank · unranked

2 citations

Vania Balderrama-Brondani, Kelsey Ruth Herrera, Brenda Chahla, Feyza Yaylaci, Roland L. Bassett +8 more

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1917

N/A

0DataRank · unranked

2 citations

John F. Ward, Wayne L. Hofstetter, David C. Rice, José A. Karam, Louis L. Pisters +24 more

Phase 2 study of monotherapy with pembrolizumab for advanced adrenocortical carcinoma

Endocrine Abstracts(2025)10.1530/endoabs.107.006

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Juhee Song, Vania Balderrama-Brondani, Feyza Yaylaci, Matthew T. Campbell +2 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more

Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Marker of HPV-Independent Disease

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.21.658950

N/A

0DataRank · unranked

0 citations

Andrew Johns, Letícia Campos Clemente, Matthew Manuel, Wei Qiao, Wei Lu +8 more

Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease

Cancers(2025)10.3390/cancers17213410

N/A

0DataRank · unranked

0 citations

Andrew Johns, Letícia Campos Clemente, Matthew Manuel, Wei Qiao, Wei Lü +8 more

Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder

ESMO Open(2024)10.1016/j.esmoop.2024.103964

N/A

0DataRank · unranked

7 citations

Andrew M. Fang, Mohammad Jad Moussa, Hyunsoo Hwang, Nathaniel R. Wilson, Matthew T. Campbell +9 more

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation

British Journal of Urology(2021)10.1111/bju.15541

N/A

0DataRank · unranked

33 citations

Aradhana M. Venkatesan, Pavlos Msaouel, Amol J. Ghia, Jing Li, D.N. Yeboa +13 more

Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac046

N/A

0DataRank · unranked

32 citations

Jeena Varghese, Stephen K. Gruschkus, Camilo Jiménez, Steven G. Waguespack, Sara Bedrose +15 more

Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship

Urologic Oncology Seminars and Original Investigations(2022)10.1016/j.urolonc.2022.10.015

N/A

0DataRank · unranked

4 citations

Zhigang Duan, Kelly K. Bree, Akshay Sood, Hui Zhao, Niyati Lobo +8 more

Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo

Acta Biomaterialia(2024)10.1016/j.actbio.2024.02.025

N/A

0DataRank · unranked

7 citations

Vanessa Parietti, Sergio Barrios, Peter D.A. Shepherd, Tianhong Pan, Wei‐Lien Wang +7 more

Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival

Urologic Oncology Seminars and Original Investigations(2021)10.1016/j.urolonc.2021.08.022

N/A

0DataRank · unranked

9 citations

Daniel D. Shapiro, Mary E. Westerman, Hyunsoo Hwang, Xuemei Wang, Luis Segarra +7 more

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases

Human Pathology(2024)10.1016/j.humpath.2024.105673

N/A

0DataRank · unranked

0 citations

Lan Zheng, Hossein Hosseini, John F. Ward, Louis L. Pisters, Matthew T. Campbell +4 more